Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)
Titel:
Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)
Auteur:
Reck, M. Socinski, M.A. Cappuzzo, F. Orlandi, F. Stroyakovskii, D. Nogami, N. Rodríguez-Abreu, D. Moro-Sibilot, D. Thomas, C.A. Barlesi, F. Finley, G. Kelsch, C. Lee, A. Coleman, S. Shen, Y. Kowanetz, M. Lopez-Chavez, A. Sandler, A. Jotte, R.